NVO – Novo Nordisk A/S
NVO — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.88
Margin Of Safety %
4
Put/Call OI Ratio
0.67
EPS Next Q Diff
-0.27
EPS Last/This Y
0.02
EPS This/Next Y
-0.17
Price
46.18
Target Price
48.6
Analyst Recom
2.47
Performance Q
2.46
Upside
15.1%
Beta
0.76
Ticker: NVO
21 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-22 | NVO | 48.13 | 0.62 | 0.55 | 1286624 |
| 2026-07-23 | NVO | 48.19 | 0.62 | 0.61 | 1298591 |
| 2026-07-24 | NVO | 48.77 | 0.62 | 0.65 | 1307041 |
| 2026-07-27 | NVO | 49.69 | 0.63 | 0.53 | 1286743 |
| 2026-07-28 | NVO | 50.79 | 0.63 | 0.40 | 1300960 |
| 2026-07-29 | NVO | 51.57 | 0.63 | 0.76 | 1315927 |
| 2026-07-30 | NVO | 51.58 | 0.63 | 0.72 | 1338202 |
| 2026-07-31 | NVO | 47.11 | 0.64 | 0.54 | 1369868 |
| 2026-08-03 | NVO | 47.09 | 0.65 | 0.53 | 1346564 |
| 2026-08-04 | NVO | 44.32 | 0.65 | 0.73 | 1387002 |
| 2026-08-05 | NVO | 44.65 | 0.65 | 0.46 | 1477644 |
| 2026-08-07 | NVO | 47.26 | 0.65 | 0.36 | 1507841 |
| 2026-08-10 | NVO | 47.73 | 0.65 | 0.97 | 1437011 |
| 2026-08-11 | NVO | 47.27 | 0.66 | 0.96 | 1457809 |
| 2026-08-12 | NVO | 46.38 | 0.66 | 0.52 | 1473602 |
| 2026-08-13 | NVO | 46.72 | 0.66 | 0.42 | 1482902 |
| 2026-08-14 | NVO | 45.9 | 0.66 | 0.15 | 1498618 |
| 2026-08-17 | NVO | 44.88 | 0.69 | 0.82 | 1439309 |
| 2026-08-18 | NVO | 45.7 | 0.68 | 0.65 | 1442099 |
| 2026-08-19 | NVO | 46.47 | 0.68 | 0.37 | 1439415 |
| 2026-08-20 | NVO | 46.18 | 0.67 | 1.33 | 1477186 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
21 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-22 | NVO | 48.19 | -15.7 | -4989.6 | 21.86 |
| 2026-07-23 | NVO | 48.19 | -15.7 | -4748.9 | 21.86 |
| 2026-07-24 | NVO | 48.78 | -16.4 | -4563.6 | 21.77 |
| 2026-07-27 | NVO | 49.67 | -16.4 | -4252.3 | 21.77 |
| 2026-07-28 | NVO | 50.96 | -16.4 | -4110.5 | 21.77 |
| 2026-07-29 | NVO | 51.59 | -16.4 | -4982.6 | 21.77 |
| 2026-07-30 | NVO | 51.59 | -16.4 | -5122.0 | 21.77 |
| 2026-07-31 | NVO | 47.12 | -16.4 | -6299.5 | 21.77 |
| 2026-08-03 | NVO | 47.09 | -16.4 | -5001.2 | 3.35 |
| 2026-08-04 | NVO | 47.09 | -16.4 | -5001.2 | 3.35 |
| 2026-08-05 | NVO | 44.49 | -16.4 | -4289.9 | 3.40 |
| 2026-08-06 | NVO | 45.97 | -16.4 | -3771.8 | 3.40 |
| 2026-08-07 | NVO | 47.24 | 4.6 | -1075.1 | 19.43 |
| 2026-08-13 | NVO | 46.73 | 14.2 | -3350.5 | 3.57 |
| 2026-08-14 | NVO | 45.89 | 14.2 | -3603.1 | 23.08 |
| 2026-08-17 | NVO | 44.89 | 14.2 | -3555.8 | 3.57 |
| 2026-08-18 | NVO | 45.70 | 14.2 | -3189.5 | 3.58 |
| 2026-08-19 | NVO | 46.47 | 14.2 | -3525.5 | 3.57 |
| 2026-08-20 | NVO | 46.18 | 14.2 | -3880.5 | 3.58 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
19 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-22 | NVO | 0 | -2.77 | 0.83 |
| 2026-07-23 | NVO | 0 | -2.77 | 0.83 |
| 2026-07-24 | NVO | 0 | -2.77 | 0.83 |
| 2026-07-27 | NVO | 0 | -3.46 | 0.93 |
| 2026-07-28 | NVO | 0 | -3.46 | 0.93 |
| 2026-07-29 | NVO | 0 | -3.46 | 0.93 |
| 2026-07-30 | NVO | 0 | -3.46 | 0.93 |
| 2026-07-31 | NVO | 0 | -3.46 | 0.93 |
| 2026-08-03 | NVO | 0 | -3.35 | 0.93 |
| 2026-08-04 | NVO | 0 | -3.35 | 0.93 |
| 2026-08-05 | NVO | 0 | -3.35 | 0.93 |
| 2026-08-06 | NVO | 0 | -3.35 | 0.93 |
| 2026-08-10 | NVO | 0 | -3.53 | 0.93 |
| 2026-08-11 | NVO | 0 | -3.53 | 0.93 |
| 2026-08-12 | NVO | 0 | -3.53 | 0.88 |
| 2026-08-13 | NVO | 0 | -3.53 | 0.88 |
| 2026-08-14 | NVO | 0 | -3.53 | 0.88 |
| 2026-08-17 | NVO | 0 | -3.43 | 0.88 |
| 2026-08-18 | NVO | 0 | -3.43 | 0.88 |
| 2026-08-19 | NVO | 0 | -3.43 | 0.88 |
| 2026-08-20 | NVO | 0.00 | -3.43 | 0.88 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
0.96
Avg. EPS Est. Current Quarter
0.8
Avg. EPS Est. Next Quarter
0.69
Insider Transactions
Institutional Transactions
-3.43
Beta
0.76
Average Sales Estimate Current Quarter
11321
Average Sales Estimate Next Quarter
11485
Fair Value
48.21
Quality Score
91
Growth Score
76
Sentiment Score
62
Actual DrawDown %
68.8
Max Drawdown 5-Year %
-74.7
Target Price
48.6
P/E
11.29
Forward P/E
13.85
PEG
P/S
3
P/B
6.03
P/Free Cash Flow
13.1
EPS
4.09
Average EPS Est. Cur. Y
3.58
EPS Next Y. (Est.)
3.42
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
35.36
Relative Volume
0.62
Return on Equity vs Sector %
26.2
Return on Equity vs Industry %
16.7
EPS 1 7Days Diff
EPS 1 30Days Diff
0.19
EBIT Estimation
-3880.5
◆
NVO
Healthcare
$46.18
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
0/20
Pullback
23/25
Volume
9/15
Valuation
14/20
TP/AR
1/10
Options
6/10
RSI
45.9
Range 1M
31.1%
Sup Dist
0.8%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
2/25
Growth
6/30
Estimates
5/20
Inst/Vol
1/15
Options
3/10
EPS Yr
-7.2%
EPS NY
-1.2%
52W%
38.5%
💎
Long-Term Value
Quality companies, undervalued
WEAK
🟡 HOLD
+0.5% upside
Quality
28/30
Valuation
6/30
Growth
5/25
Stability
3/10
LT Trend
1/5
Upside
+0.5%
Quality
91
MoS
4%
Click a card to see score breakdown
Full Analysis →
NVO — P/E HistoricalDrug Manufacturers - General
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 66700
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NVO
Latest News
—
Caricamento notizie per NVO…
stock quote shares NVO – Novo Nordisk A/S Stock Price stock today
news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch NVO – Novo Nordisk A/S yahoo finance google finance
stock history NVO – Novo Nordisk A/S invest stock market
stock prices NVO premarket after hours
ticker NVO fair value insiders trading